EP1815853B1 - Therapeutic agent ((-)-bpap) for drug dependence - Google Patents
Therapeutic agent ((-)-bpap) for drug dependence Download PDFInfo
- Publication number
- EP1815853B1 EP1815853B1 EP05809728A EP05809728A EP1815853B1 EP 1815853 B1 EP1815853 B1 EP 1815853B1 EP 05809728 A EP05809728 A EP 05809728A EP 05809728 A EP05809728 A EP 05809728A EP 1815853 B1 EP1815853 B1 EP 1815853B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- substance
- present
- compound
- therapeutic agent
- dependence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Definitions
- the present invention relates to a therapeutic agent for substance dependence, which comprises (-)-1-(benzofuran-2-yl)-2- propylaminopentane or a pharmaceutically acceptable acid addition salt thereof as an active ingredient.
- Substance dependence as defined by the WHO is "A state, psychic and sometimes also physical, resulting from the interaction between a living organism and a drug, characterized by behavioural and other responses that always include a compulsion to take the drug on a continuous or periodic basis in order to experience its psychic effects, and sometimes to avoid the discomfort of its absence.”
- substance dependence can be divided into psychic dependence and physical dependence.
- psychic dependence there appears a strong desire "craving" for taking a certain substance, and in physical dependence, withdrawal symptoms appear upon interruption of dosing.
- a dependence-producing substance may also produce tolerance in those who take it, thus causing an increase in intake thereof.
- craving for a large amount of a substance is brought about due to extreme suffering, thus falling in a vicious cycle to make impossible to keep away from the substance. This vicious cycle constitutes substance dependence.
- Substances causing substance dependence include stimulants (amphetamine, methamphetamine, MDMA), opioids (morphine, heroin), barbiturate type anesthetics, hallucinogens (LSD), ***e, hemp (marijuana), cannabis, benzodiazepine type compounds (sedatives, hypnotics, anxiolytics), alcohol, and volatile organic solvents.
- stimulants amphetamine, methamphetamine, MDMA
- opioids morphine, heroin
- barbiturate type anesthetics barbiturate type anesthetics
- LSD hallucinogens
- ***e e.g., benzodiazepine type compounds
- Some stimulant substances have an appetite-suppressing effect and are thus used sometimes for dieting. It is also noted that some stimulant substances are mixed in "diet pills". These drugs are those regarded as most important for measures against drug abuse in Japan because of the hazardous nature and prevalence thereof.
- Various problems with substance dependence are not only medical problems but
- psychopathic symptom is increasingly experienced as chronic effect.
- symptom examples include hyperacusia by which ambient sounds are heard louder than actual sounds and auditory hallucinations by which voices are heard in one's head, together with the noise of an air conditioner and the sound of running water, or voices coming from nowhere are heard without relation to such noise or sound.
- Such voices may be voices of his family, friends, acquaintances in some cases or completely unfamiliar voices in other cases and are heard to be accusatory, threatening, mandatory or interfering. If his life or inner thoughts are guessed rightly by the voices, he believes that a device such as a bugging device has been set somewhere, and will seek for it under the roof or floor or will disassemble electrical utility equipments.
- Patent Document 1 discloses azabicyclo derivatives or benzoic acid derivatives (5-HT antagonist); Patent Document 2 discloses rolipram (phosphodiesterase inhibitor); Patent Document 3 discloses ifenprodil; Patent Document 4 discloses an inhibitor of degradation of an endogenous neuropeptidyl opioid; and Japanese Patent 5 discloses prophylaxis/therapy of substance dependence caused by dopamine autoreceptor agonists etc., as well as alleviation/prophylaxis of withdrawal syndrome.
- Germanien et al., Pharmacol. Ther. 84, 133-156 (1999 ) propose dopamine receptors as possible targets for treatment of substance dependence and examine potential benefits of dopaminergic therapy in the treatment of substance dependence.
- any of these therapeutic agents for substance dependence cannot be said to be satisfactory in their effect and are still not put to practical use.
- the inventors sought the mechanism of relapse/recurrence of craving for substance using a behavioral pharmacological and biochemical approach, that is, they made an intensive study using a drug self-administration procedure in order to develop therapeutic agents for substance dependence as well as to elucidate the mechanism of relapse/recurrence.
- an experimental animal is allowed to learn the drug self-administration behavior of pressing a lever to attain a substance.
- the animal is given a substance-containing solution simultaneously with a light-tone stimulus.
- the substance-containing solution is replaced by physiological saline.
- the behavior of eagerly pressing the lever for acquiring the substance comes to be observed in the experimental animal having learned the substance self-administration behavior.
- This behavior is regarded as substance-seeking behavior.
- This substance-seeking behavior is gradually decreased by repeated infusion of physiological saline and is eventually extinguished.
- the inventors sought the mechanism of relapse/recurrence of craving for substance behavioral pharmacologically and biochemically using this drug self-administration procedure. As a result they found that (-)-1-(benzofuran-2-yl)-2-propylaminopentane known previously as a compound having a psychotropic effect, an antidepressant activity, and an antiparkinsonian effect or anti-Alzheimer disease effect has an excellent effect as a therapeutic agent for substance dependence, and the present invention was thereby completed. That is, the present invention provides:
- the (-)-1-(benzofuran-2-yl)-2-propylaminopentane used in the present invention (also referred to in this specification as "the compound of the present invention") is a known compound having the chemical structure represented by formula I below, and International Publication WO00/26204 describes its psychotropic effect, antidepressant activity, antiparkinsonian effect or anti-Alzheimer disease effect together with its production method and physical properties.
- the compound of the present invention has been connected to conferring unique survival activity on cortical neurons through sigma receptors ( Hanabe et al., Cell Mol Neurobiol 20, 695-702 (2000 )). It also displays neuroprotective effects attributable to antiapoptotic effect ( Life Sciences 72, 2785-2792 (2003 )) and improves the reduction in spontaneous motor activity induced by reserpine, suggesting that its effect is mediated by an increase in dopamine release ( Eur. J. Pharmacol. 421, 181-189 (2001 )). The use of the compound of the present invention as a therapeutic agent for substance dependence has never been reported in any literatures including those mentioned above.
- pharmacologically acceptable acid addition salts of (-)-1-(benzofuran-2-yl)-2-propylaminopentane used in the present invention include addition salts of inorganic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid and methanesulfonic acid or organic acids such as gluconic acid, tartaric acid, maleic acid, fumaric acid, succinic acid, malic acid, citric acid and mandelic acid.
- inorganic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid and methanesulfonic acid
- organic acids such as gluconic acid, tartaric acid, maleic acid, fumaric acid, succinic acid, malic acid, citric acid and mandelic acid.
- the compound used in the present invention and its pharmaceutically acceptable acid addition salt when used as the pharmaceutical preparation described above, can be mixed usually with a carrier, excipient, diluent, solubilizing agent etc. and safely administered orally or parenterally in the form of tablets, powders, granules, capsules, syrup, injection or the like.
- the dosage can vary depending on a variety of factors such as medical condition, age, sex, weight of the patient, the pharmaceutical preparation can be administered to an adult usually once or several times orally in an amount of about 0.1 mg to 1000 mg, preferably 1 mg to 500 mg, per day.
- an effective and minimum dose is preferably selected.
- the substance dependence in the present invention includes that is attributable to abuse of substances or chemical substances such as stimulants (amphetamine, methamphetamine, MDMA), opiods (morphine, heroin), barbiturate type anesthetics, hallucinogens (LSD), ***e, hemp (marijuana), cannabis, benzodiazepine type compounds (sedatives, hypnotics, anxiolytics), alcohol, and volatile organic solvents.
- stimulants amphetamine, methamphetamine, MDMA
- opiods morphine, heroin
- barbiturate type anesthetics barbiturate type anesthetics
- hallucinogens LSD
- ***e hemp (marijuana)
- hemp marijuana
- cannabis benzodiazepine type compounds (sedatives, hypnotics, anxiolytics), alcohol, and volatile organic solvents.
- a catheter for self-administration of methamphetamine (inner diameter of 0.5 mm, outer diameter of 1.0 mm) was inserted into the right jugular vein of male Wister/ST rats (250 to 350 g), and the end of the catheter was anchored to just outside the right atrium.
- An operant box used in the experiment was equipped with 2 levers.
- FR1 fixed-ratio 1
- the other is an inactive lever by which neither the drug-associated cue nor the infusion of methamphetamine are given.
- methamphetamine self-administration behavior methamphetamine-taking behavior
- physiological saline was substituted for methamphetamine, to carry out an extinction process for 5 days (1 hour per session without drug-associated cue).
- the number of pressing the 2 levers (the active lever and inactive lever) by the experimental animal was used as an indicator of the substance-seeking behavior.
- substance-seeking behavior was induced by drug-associated cue (tone and light) or by administering a low dose of methamphetamine (1.0 mg/kg, intraperitoneal (i.p.) administration).
- methamphetamine 1.0 mg/kg, intraperitoneal (i.p.) administration.
- signal administration of the compound of the present invention 0.2, 1.0 mg/kg, i.p. was carried out, and a change in the methamphetamine-seeking behavior induced by drug-associated cue or by forced administration of methamphetamine was observed.
- the seeking behavior was suppressed significantly and dose-dependently ( Figs. 1 and 2 ).
- the compound of the present invention (1.0 mg/kg, i.p.) was repeatedly administered, and a change in the methamphetamine-seeking behavior induced by drug-associated cue or by forced administration of methamphetamine was observed. As a result, the seeking behavior was suppressed significantly ( Figs. 3 and 4 ).
- the compound of the present invention (0.32, 1.0 mg/kg, i.p.) and a dopamine D1 receptor antagonist SCH23390, (R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2, 3,4, 5-tetrahydro-1H-3-benza zepin hydrochloride) (0.0001 mg/kg, s.c.) or a D2 receptor antagonist sultopride were administered.
- the methamphetamine-seeking behavior induced by drug-associated cue showed a tendency to be antagonized by the dopamine D1 receptor antagonist SCH23390 (0.0001 mg/kg, s.c.), but not by the dopamine D2 receptor antagonist sultopride (10 mg/kg, i.p.) ( Fig. 7 ).
- the methamphetamine-seeking behavior induced by administering a low dose of methamphetamine was antagonized by the dopamine D1 receptor antagonist SCH23390 (0.001 mg/kg, s.c.), but not by the dopamine D2 receptor antagonist sultopride (10 mg/kg, i.p.) ( Fig. 8 ).
- the frequency of lever-pressings was significantly increased by drug-associated cue or by forced administration of methamphetamine, and the methamphetamine-seeking behavior was recognized.
- This methamphetamine-seeking behavior was significantly suppressed by repeated administration in the extinction process for 5 days or even by single administration 30 minutes before measurement of methamphetamine-seeking behavior.
- the compound of the present invention at a dose that suppressed the methamphetamine-seeking behavior did not induce the methamphetamine-seeking behavior. It is suggested that the effect of the compound of the present invention is attributable to the inactivation of dopamine D1 receptor.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- The present invention relates to a therapeutic agent for substance dependence, which comprises (-)-1-(benzofuran-2-yl)-2- propylaminopentane or a pharmaceutically acceptable acid addition salt thereof as an active ingredient.
- Substance dependence as defined by the WHO is "A state, psychic and sometimes also physical, resulting from the interaction between a living organism and a drug, characterized by behavioural and other responses that always include a compulsion to take the drug on a continuous or periodic basis in order to experience its psychic effects, and sometimes to avoid the discomfort of its absence.". That is, substance dependence can be divided into psychic dependence and physical dependence. In psychic dependence, there appears a strong desire "craving" for taking a certain substance, and in physical dependence, withdrawal symptoms appear upon interruption of dosing. A dependence-producing substance may also produce tolerance in those who take it, thus causing an increase in intake thereof. In the withdrawal syndrome, craving for a large amount of a substance is brought about due to extreme suffering, thus falling in a vicious cycle to make impossible to keep away from the substance. This vicious cycle constitutes substance dependence.
- Substances causing substance dependence include stimulants (amphetamine, methamphetamine, MDMA), opioids (morphine, heroin), barbiturate type anesthetics, hallucinogens (LSD), ***e, hemp (marijuana), cannabis, benzodiazepine type compounds (sedatives, hypnotics, anxiolytics), alcohol, and volatile organic solvents. Some stimulant substances have an appetite-suppressing effect and are thus used sometimes for dieting. It is also noted that some stimulant substances are mixed in "diet pills". These drugs are those regarded as most important for measures against drug abuse in Japan because of the hazardous nature and prevalence thereof. Various problems with substance dependence are not only medical problems but also serious social problems.
- If drug abuse is repeated, psychopathic symptom is increasingly experienced as chronic effect. Frequently found symptom examples include hyperacusia by which ambient sounds are heard louder than actual sounds and auditory hallucinations by which voices are heard in one's head, together with the noise of an air conditioner and the sound of running water, or voices coming from nowhere are heard without relation to such noise or sound. Such voices may be voices of his family, friends, acquaintances in some cases or completely unfamiliar voices in other cases and are heard to be accusatory, threatening, mandatory or interfering. If his life or inner thoughts are guessed rightly by the voices, he believes that a device such as a bugging device has been set somewhere, and will seek for it under the roof or floor or will disassemble electrical utility equipments. Inextricably linked to such false feeling, he comes to have a suspicion of being soiled by someone and harbors suspicion against his family and friends or becomes paranoid. Everywhere he goes, he has the idea of being chased by a person (for example, a policeman, a mafia member etc.) or has a visual hallucination that he saw that person lurking in the shadows. Such hallucinations and delusions resemble those of schizophrenia. There are also cases where the subtleties of emotion, or willingness, are attenuated through drug abuse for a prolonged period, and hallucinations and delusions in such cases may be hardly discriminated from those of schizophrenia.
- The problem of psychopathic symptom caused by substance abuse lies in long-term persistence after chronic abuse, and in relapse due to alcohol drinking, sleeplessness, extreme stress etc. The former is called sequelae of substance abuse and the latter is called flashback phenomenon. Such pathology lasting long even after abstinence from substance use are obstacles for people who wish to recover from substance dependence, and this is another fear of substance abuse.
- Therapy of substance dependence at present is initiated by abstaining from its causative substance, and substance therapy has been regarded as having little effect. If a sleeping pill or tranquilizer is administered without careful consideration, abuse of, or dependence on, such a prescription drugs may be caused, and in fact it is said that there are many patients with abuse of prescription drugs in addition to stimulant abuse.
- As prior arts relating to therapeutic agents for substance dependence, Patent Document 1 discloses azabicyclo derivatives or benzoic acid derivatives (5-HT antagonist); Patent Document 2 discloses rolipram (phosphodiesterase inhibitor); Patent Document 3 discloses ifenprodil; Patent Document 4 discloses an inhibitor of degradation of an endogenous neuropeptidyl opioid; and Japanese Patent 5 discloses prophylaxis/therapy of substance dependence caused by dopamine autoreceptor agonists etc., as well as alleviation/prophylaxis of withdrawal syndrome.
Emilien et al., Pharmacol. Ther. 84, 133-156 (1999) propose dopamine receptors as possible targets for treatment of substance dependence and examine potential benefits of dopaminergic therapy in the treatment of substance dependence. However, any of these therapeutic agents for substance dependence cannot be said to be satisfactory in their effect and are still not put to practical use. - Patent Document 1: Japanese Patent No.
2765845 - Patent Document 2:
JP-A1-H0 9-221423 - Patent Document 3:
JP-A1-H 11-29476 - Patent Document 4: Pamphlet of International Publication
WO89/03211 - Patent Document 5: Western Germany Patent Application (Laid-Open) No.
3930282 - Accordingly, the inventors sought the mechanism of relapse/recurrence of craving for substance using a behavioral pharmacological and biochemical approach, that is, they made an intensive study using a drug self-administration procedure in order to develop therapeutic agents for substance dependence as well as to elucidate the mechanism of relapse/recurrence.
- The drug self-administration procedure as referred to herein is outlined as follows:
- First, an experimental animal is allowed to learn the drug self-administration behavior of pressing a lever to attain a substance. The animal is given a substance-containing solution simultaneously with a light-tone stimulus. After the animal is allowed to learn the substance self-administration behavior, the substance-containing solution is replaced by physiological saline. The behavior of eagerly pressing the lever for acquiring the substance comes to be observed in the experimental animal having learned the substance self-administration behavior. This behavior is regarded as substance-seeking behavior. This substance-seeking behavior is gradually decreased by repeated infusion of physiological saline and is eventually extinguished. However, the substance-seeking behavior will recur by the same light-tone stimulus (drug-associated stimuli) used during the self-administration training to the experimental animal or by administrating a substance inducing the central stimulant effect. This experimental system was used to examine the effect of various compounds.
- The inventors sought the mechanism of relapse/recurrence of craving for substance behavioral pharmacologically and biochemically using this drug self-administration procedure. As a result they found that (-)-1-(benzofuran-2-yl)-2-propylaminopentane known previously as a compound having a psychotropic effect, an antidepressant activity, and an antiparkinsonian effect or anti-Alzheimer disease effect has an excellent effect as a therapeutic agent for substance dependence, and the present invention was thereby completed. That is, the present invention provides:
- (1) A therapeutic agent for use in treating substance dependence, which comprises (-)-1-(benzofuran-2-yl)-2-propylaminopentane or a pharmaceutically acceptable acid addition salt thereof as an active ingredient;
- (2) The therapeutic agent for use in treating substance dependence according to the above (1), which suppresses the induction of substance-seeking behavior caused by substance dependence;
- (3) The therapeutic agent for use in treating substance dependence according to the above (1), wherein the substance dependence is caused by stimulant substances, opioids, barbiturate type anesthetics, hallucinogens, ***e, hemp, cannabis, alcohol, or volatile organic solvents;
- (4) The therapeutic agent for use in treating substance dependence according to the above (1) or (2), wherein the substance dependence is caused by stimulants;
- (5) The use of (-)-1-(benzofuran-2-yl)-2-propylaminopentane for preparing a medicament for the treatment of substance dependence; and
- (6) The use of the above (5), wherein the medicament suppresses the induction of substance-seeking behavior caused by substance dependence.
- The (-)-1-(benzofuran-2-yl)-2-propylaminopentane used in the present invention (also referred to in this specification as "the compound of the present invention") is a known compound having the chemical structure represented by formula I below, and International Publication
WO00/26204 - The compound of the present invention has been connected to conferring unique survival activity on cortical neurons through sigma receptors (Hanabe et al., Cell Mol Neurobiol 20, 695-702 (2000)). It also displays neuroprotective effects attributable to antiapoptotic effect (Life Sciences 72, 2785-2792 (2003)) and improves the reduction in spontaneous motor activity induced by reserpine, suggesting that its effect is mediated by an increase in dopamine release (Eur. J. Pharmacol. 421, 181-189 (2001)). The use of the compound of the present invention as a therapeutic agent for substance dependence has never been reported in any literatures including those mentioned above.
- Specific examples of pharmacologically acceptable acid addition salts of (-)-1-(benzofuran-2-yl)-2-propylaminopentane used in the present invention include addition salts of inorganic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid and methanesulfonic acid or organic acids such as gluconic acid, tartaric acid, maleic acid, fumaric acid, succinic acid, malic acid, citric acid and mandelic acid.
- The compound used in the present invention and its pharmaceutically acceptable acid addition salt, when used as the pharmaceutical preparation described above, can be mixed usually with a carrier, excipient, diluent, solubilizing agent etc. and safely administered orally or parenterally in the form of tablets, powders, granules, capsules, syrup, injection or the like. Although the dosage can vary depending on a variety of factors such as medical condition, age, sex, weight of the patient, the pharmaceutical preparation can be administered to an adult usually once or several times orally in an amount of about 0.1 mg to 1000 mg, preferably 1 mg to 500 mg, per day. However, when the dose administered once is too high, the substance-seeking behavior may be caused in some cases, and thus an effective and minimum dose is preferably selected.
- The substance dependence in the present invention includes that is attributable to abuse of substances or chemical substances such as stimulants (amphetamine, methamphetamine, MDMA), opiods (morphine, heroin), barbiturate type anesthetics, hallucinogens (LSD), ***e, hemp (marijuana), cannabis, benzodiazepine type compounds (sedatives, hypnotics, anxiolytics), alcohol, and volatile organic solvents.
-
-
Fig. 1 is a graph showing the inhibitory effect of the compound of the present invention on the substance-seeking behavior by single administration. After single administration of the compound of the present invention (1.0 mg/kg, i.p.), the number of active lever-pressings, indicating the methamphetamine seeking behavior induced by drug-associated cue, was observed for 30 minutes, and the result is shown in the graph. The symbol * indicates statistical significance vs. a non-treated group at the following levels * : p<0.005, ** : p<0.01, *** : p<0.001. The symbol # indicates statistical significance vs. a physiological saline-treated group at the following levels # p<0.05, ## :p<0.01, ###: p<0.001. This description of * and # will hereinafter applies. -
Fig. 2 is a graph showing the inhibitory effect of the compound of the present invention on the substance-seeking behavior by single administration. After single administration of the compound of the present invention (1.0 mg/kg, i.p.), the number of active lever-pressings induced by forced administration of a low dose of methamphetamine, was observed for 30 minutes, and the result is shown in the graph. -
Fig. 3 is a graph showing the inhibitory effect of the compound of the present invention on the substance-seeking behavior by repeated administration. After repeated administration of the compound of the present invention (1.0 mg/kg, i.p.), the number of active lever-pressings induced by drug-associated cue, was observed for 30 minutes, and the result is shown in the graph. -
Fig. 4 is a graph showing the inhibitory effect of the compound of the present invention on the substance-seeking behavior by repeated administration. After repeated administration of the compound of the present invention (1.0 mg/kg, i.p.), the number of active lever-pressings induced by forced administration of a low dose of methamphetamine, was observed for 30 minutes, and the result is shown in the graph. -
Fig. 5 is a graph showing the influence of the compound of the present invention on methamphetamine self-administration. After administration of the compound of the present invention (1.0 mg/kg, i.p.), the number of active lever-pressings by which methamphetamine was self-administered was observed for 30 minutes, and the result is shown in the graph. -
Fig. 6 is a graph showing the influence of the compound of the present invention on occurrence of substance-seeking behavior. The number of active lever-pressings after administration of the compound of the present invention (1.0 mg/kg, 3.2 mg/kg, 10 mg/kg, i.p.) was observed for 30 minutes, and the result is shown in the graph. -
Fig. 7 is a graph showing the effect of the compound of the present invention in the coexistence of a dopamine D1 or D2 receptor antagonist. After single administration of the compound of the present invention (1.0 mg/kg, i.p.), dopamine D1 receptor antagonist SCH23390, (R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benza zepine hydrochloride) (0.0001 mg/kg, s.c.) or a D2 receptor antagonist sultopride, the number of active lever-pressings induced by drug-associated cue, was observed for 30 minutes, and the result is shown in the graph. -
Fig. 8 is a graph showing the effect of the compound of the present invention in the coexistence of a dopamine D1 or D2 receptor antagonist. After single administration of the compound of the present invention (1.0 mg/kg, i.p.) and a dopamine D1 receptor antagonist SCH23390, (R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benza zepine hydrochloride) (0.0001 mg/kg, s.c.) or a D2 receptor antagonist sultopride, the number of active lerver-pressings induced by forced administration of a low dose of methamphetamine, was observed for 30 minutes, and the result is shown in the graph. The symbol + indicates statistical significance + : p<0.05 vs. a treated group with 1.0 mg/kg of the compound of the present invention. - Hereinafter, the present invention is described in more detail by reference to the Example (Experimental Examples).
- Using methamphetamine as an addictive substance, the following experiments were carried out according to a method described in Neuropsychopharmacology, 29, 1470-1478 (2004).
- A catheter for self-administration of methamphetamine (inner diameter of 0.5 mm, outer diameter of 1.0 mm) was inserted into the right jugular vein of male Wister/ST rats (250 to 350 g), and the end of the catheter was anchored to just outside the right atrium. An operant box used in the experiment was equipped with 2 levers. One is an active lever by which when pressed once (fixed-ratio 1 (FR1)), infusions of a very low dose of methamphetamine (0.02 mg per injection) was paired with onset of a 6-sec tone (70 dB/7 kHz) and light (300 lux) compound stimulus. The other is an inactive lever by which neither the drug-associated cue nor the infusion of methamphetamine are given.
After the animal was allowed to get methamphetamine self-administration behavior (methamphetamine-taking behavior) by the self-administration experiment for 10 days (2 hours per session), physiological saline was substituted for methamphetamine, to carry out an extinction process for 5 days (1 hour per session without drug-associated cue).
The hydrochloride compound of the present invention used in the experiment had a melting point of 165.0 to 166.0°C, an optical purity of 93%ee and specific rotation: [α]D 20= -4.08 (c = 4.0 methanol).
The number of pressing the 2 levers (the active lever and inactive lever) by the experimental animal was used as an indicator of the substance-seeking behavior. - On day 6 of the extinction process, substance-seeking behavior ("craving") was induced by drug-associated cue (tone and light) or by administering a low dose of methamphetamine (1.0 mg/kg, intraperitoneal (i.p.) administration).
Thirty minutes before this stimulation with the drug-associated cue or by the administration of a low dose of methamphetamine, signal administration of the compound of the present invention (0.32, 1.0 mg/kg, i.p.) was carried out, and a change in the methamphetamine-seeking behavior induced by drug-associated cue or by forced administration of methamphetamine was observed. As a result, the seeking behavior was suppressed significantly and dose-dependently (Figs. 1 and2 ). - In the extinction process for 5 days, the compound of the present invention (1.0 mg/kg, i.p.) was repeatedly administered, and a change in the methamphetamine-seeking behavior induced by drug-associated cue or by forced administration of methamphetamine was observed. As a result, the seeking behavior was suppressed significantly (
Figs. 3 and4 ). - For examining the influence of the compound of the present invention on methamphetamine-taking behavior, 1.0 mg/kg of the compound of the present invention was administered intraperitoneally. As a result, the number of active lever pressings, by which the experimental animal could attain the self-administration (taking) of methamphetamine, was not increased, thus revealing that the compound of the present invention did not exert any influence on the methamphetamine-taking behavior (
Fig. 5 ). - For examining the influence of the compound of the present invention on occurrence of substance-seeking behavior, 1.0 mg/kg of the compound of the present invention was administered intraperitoneally As a result, the methamphetamine seeking behavior was not induced. However, the compound of the present invention at a high dose (10 mg/kg, i.p.), although weak, caused methamphetamine-seeking behavior (
Fig. 6 ). - On day 6 of the extinction process, substance-seeking behavior ("craving") was induced by drug-associated cue (tone and light) or by administering a low dose of methamphetamine (1.0 mg/kg, intraperitoneal (i.p.) administration).
Thirty minutes before drug-associated cue or by the administration of a low dose of methamphetamine, the compound of the present invention (0.32, 1.0 mg/kg, i.p.) and a dopamine D1 receptor antagonist SCH23390, (R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2, 3,4, 5-tetrahydro-1H-3-benza zepin hydrochloride) (0.0001 mg/kg, s.c.) or a D2 receptor antagonist sultopride were administered. The methamphetamine-seeking behavior induced by drug-associated cue showed a tendency to be antagonized by the dopamine D1 receptor antagonist SCH23390 (0.0001 mg/kg, s.c.), but not by the dopamine D2 receptor antagonist sultopride (10 mg/kg, i.p.) (Fig. 7 ). The methamphetamine-seeking behavior induced by administering a low dose of methamphetamine was antagonized by the dopamine D1 receptor antagonist SCH23390 (0.001 mg/kg, s.c.), but not by the dopamine D2 receptor antagonist sultopride (10 mg/kg, i.p.) (Fig. 8 ). - As is evident from the experiments shown above, the frequency of lever-pressings was significantly increased by drug-associated cue or by forced administration of methamphetamine, and the methamphetamine-seeking behavior was recognized. This methamphetamine-seeking behavior was significantly suppressed by repeated administration in the extinction process for 5 days or even by
single administration 30 minutes before measurement of methamphetamine-seeking behavior. The compound of the present invention at a dose that suppressed the methamphetamine-seeking behavior did not induce the methamphetamine-seeking behavior. It is suggested that the effect of the compound of the present invention is attributable to the inactivation of dopamine D1 receptor.
Claims (6)
- A therapeutic agent for use in treating substance dependence, which comprises (-)-1-(benzofuran-2-yl)-2-propylaminopentane or a pharmaceutically acceptable acid addition salt thereof as an active ingredient.
- The therapeutic agent for use in treating substance dependence according to claim 1, which suppresses the induction of substance-seeking behavior caused by substance dependence.
- The therapeutic agent for use in treating substance dependence according to claim 1, wherein the substance dependence is caused by stimulant substances, opioids, barbiturate type anesthetics, hallucinogens, ***e, hemp, cannabis, alcohol, or volatile organic solvents.
- The therapeutic agent for use in treating substance dependence according to claim 1 or 2, wherein the substance dependence is caused by stimulants.
- Use of (-)-1-(benzofuran-2-yl)-2-propylaminopentane for preparing a medicament for the treatment of substance dependence.
- The use of claim 5, wherein the medicament suppresses the induction of substance-seeking behavior caused by substance dependence.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200530730T SI1815853T1 (en) | 2004-11-25 | 2005-11-21 | Therapeutic agent ((-)-bpap) for drug dependence |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004339996A JP5030194B2 (en) | 2004-11-25 | 2004-11-25 | Drug dependence treatment |
PCT/JP2005/021344 WO2006057211A1 (en) | 2004-11-25 | 2005-11-21 | Therapeutic agent for drug dependence |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1815853A1 EP1815853A1 (en) | 2007-08-08 |
EP1815853A4 EP1815853A4 (en) | 2008-03-19 |
EP1815853B1 true EP1815853B1 (en) | 2009-04-22 |
Family
ID=36497948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05809728A Not-in-force EP1815853B1 (en) | 2004-11-25 | 2005-11-21 | Therapeutic agent ((-)-bpap) for drug dependence |
Country Status (15)
Country | Link |
---|---|
US (2) | US7825158B2 (en) |
EP (1) | EP1815853B1 (en) |
JP (1) | JP5030194B2 (en) |
KR (1) | KR101096416B1 (en) |
CN (1) | CN101065123B (en) |
AT (1) | ATE429219T1 (en) |
AU (1) | AU2005308258B2 (en) |
CA (1) | CA2589289C (en) |
DE (1) | DE602005014135D1 (en) |
DK (1) | DK1815853T3 (en) |
ES (1) | ES2325790T3 (en) |
HK (1) | HK1113309A1 (en) |
IL (1) | IL183028A (en) |
SI (1) | SI1815853T1 (en) |
WO (1) | WO2006057211A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101500022B1 (en) * | 2007-06-21 | 2015-03-06 | 가부시키가이샤 후지모토 코포레이션 | composition for transdermal or transmucosal administration |
AU2014371437B2 (en) | 2013-12-25 | 2020-01-30 | Fujimoto Co., Ltd. | Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder |
HUE050756T2 (en) | 2014-12-05 | 2021-01-28 | Semmelweis Univ | Arylalkylamine compounds for use in the prevention or treatment of cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2765845B2 (en) | 1986-11-21 | 1998-06-18 | グラクソ、グループ、リミテッド | Remedies for prevention of discontinuation syndrome |
ATE91891T1 (en) | 1987-10-07 | 1993-08-15 | Matrix Technologies Inc | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COCAINE ADDICTION. |
DE3930282A1 (en) | 1989-09-11 | 1991-03-21 | Boehringer Ingelheim Kg | USE OF DOPAMINE AUTOREZONE AGONISTS IN THE TREATMENT OF DRUG DEPENDENCE |
JP3601898B2 (en) | 1996-02-14 | 2004-12-15 | 俊隆 鍋島 | Drug-dependent formation inhibitor |
JPH1129476A (en) | 1997-05-16 | 1999-02-02 | Grelan Pharmaceut Co Ltd | Depressant for drug dependence |
JP4499208B2 (en) * | 1998-10-29 | 2010-07-07 | 株式会社フジモト・コーポレーション | Novel optically active aminopentane derivatives |
JP4691230B2 (en) * | 2000-04-11 | 2011-06-01 | 株式会社フジモト・コーポレーション | Process for producing optically active 1- (benzofuran-2-yl) -2-propylaminopentane |
JP4953040B2 (en) * | 2001-09-19 | 2012-06-13 | 株式会社フジモト・コーポレーション | Apoptosis inhibitor |
JP4953041B2 (en) * | 2001-09-19 | 2012-06-13 | 株式会社フジモト・コーポレーション | Apoptosis inhibitor |
-
2004
- 2004-11-25 JP JP2004339996A patent/JP5030194B2/en active Active
-
2005
- 2005-11-21 AU AU2005308258A patent/AU2005308258B2/en not_active Ceased
- 2005-11-21 AT AT05809728T patent/ATE429219T1/en active
- 2005-11-21 CN CN2005800405647A patent/CN101065123B/en not_active Expired - Fee Related
- 2005-11-21 WO PCT/JP2005/021344 patent/WO2006057211A1/en active Application Filing
- 2005-11-21 SI SI200530730T patent/SI1815853T1/en unknown
- 2005-11-21 EP EP05809728A patent/EP1815853B1/en not_active Not-in-force
- 2005-11-21 CA CA2589289A patent/CA2589289C/en not_active Expired - Fee Related
- 2005-11-21 KR KR1020077012243A patent/KR101096416B1/en active IP Right Grant
- 2005-11-21 US US11/791,116 patent/US7825158B2/en not_active Expired - Fee Related
- 2005-11-21 DK DK05809728T patent/DK1815853T3/en active
- 2005-11-21 DE DE602005014135T patent/DE602005014135D1/en active Active
- 2005-11-21 ES ES05809728T patent/ES2325790T3/en active Active
-
2007
- 2007-05-07 IL IL183028A patent/IL183028A/en active IP Right Grant
-
2008
- 2008-03-27 HK HK08103420.6A patent/HK1113309A1/en not_active IP Right Cessation
-
2010
- 2010-08-05 US US12/851,091 patent/US8318799B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ATE429219T1 (en) | 2009-05-15 |
WO2006057211A1 (en) | 2006-06-01 |
US7825158B2 (en) | 2010-11-02 |
DE602005014135D1 (en) | 2009-06-04 |
US8318799B2 (en) | 2012-11-27 |
IL183028A (en) | 2011-12-29 |
EP1815853A1 (en) | 2007-08-08 |
AU2005308258B2 (en) | 2011-02-24 |
EP1815853A4 (en) | 2008-03-19 |
IL183028A0 (en) | 2007-10-31 |
DK1815853T3 (en) | 2009-08-03 |
AU2005308258A1 (en) | 2006-06-01 |
CN101065123B (en) | 2012-02-15 |
CA2589289C (en) | 2013-04-30 |
ES2325790T3 (en) | 2009-09-17 |
JP5030194B2 (en) | 2012-09-19 |
JP2006151820A (en) | 2006-06-15 |
CA2589289A1 (en) | 2006-06-01 |
KR20070091610A (en) | 2007-09-11 |
HK1113309A1 (en) | 2008-10-03 |
SI1815853T1 (en) | 2009-10-31 |
US20100298426A1 (en) | 2010-11-25 |
KR101096416B1 (en) | 2011-12-21 |
CN101065123A (en) | 2007-10-31 |
US20080004337A1 (en) | 2008-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
R. Alper, Howard S. Lotsof, Geerte MN Frenken, Daniel J. Luciano, Jan Bastiaans | Treatment of acute opioid withdrawal with ibogaine | |
RU2281771C2 (en) | Use of dextromethorphan and oxidase inhibitor for removing addiction to narcotics and antidepressants in patients | |
RU2492858C2 (en) | Compositions and methods of preventing and treating addictions | |
Grounds et al. | Intensive Care Society Review of Best Practice for Analgesia and Sedation in the Critical Care | |
EP1773306A1 (en) | Medicament for the treatment of central nervous system disorders | |
RU2322977C1 (en) | Synthetic analgesic agent and method for treatment based on this agent | |
Freitas et al. | Effects of nicotinic acetylcholine receptor agonists in assays of acute pain-stimulated and pain-depressed behaviors in rats | |
US8318799B2 (en) | Therapeutic agent for substance dependence | |
CN111135170A (en) | Use of bulleyaconitine A compound in treating psychological dependence of addictive substance | |
US20240216339A1 (en) | Methods of treating neuropsychiatric disorders | |
Ojanperä et al. | Buprenorphine, Polydrug Use, and Deaths | |
Aliyu et al. | Therapeutic potential of pomegranate antioxidant compounds in ameliorating opiate addiction | |
Truong | Novel Psychoactive Substances | |
WO2011145062A1 (en) | Treatment of tinnitus and related auditory dysfunctions | |
Mitchell | A comparison of methadone and slow-release oral morphine as maintenance pharmacotherapies for opioid dependence | |
JP2006151820A5 (en) | ||
AU2004200969B2 (en) | Use of dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants | |
Gabel et al. | Opioid Use and Addictive Disorder | |
US20020137767A1 (en) | Methods for treating addictive disorders | |
Vannucchi et al. | Paresthesia During Naltrexone Treatment: A Case Report | |
Rotgers | rain usance | |
Lindsey | Effects of monoamine transporter blockers on ***e self-administration: Relation to dopamine transporter occupancy measured by PET in rhesus monkeys. An investigation of substitute agonist therapeutic strategies for ***e addiction | |
Athanasos | Opioid maintained subjects and the effects of high dose morphine and adjuvant analgesics. | |
Gerevich et al. | eve&rave-Das Schweizer Drogenforum für risikobewussten und selbstverantwortlichen Umgang mit Drogen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070510 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080219 |
|
17Q | First examination report despatched |
Effective date: 20080415 |
|
RTI1 | Title (correction) |
Free format text: THERAPEUTIC AGENT ((-)-BPAP) FOR DRUG DEPENDENCE |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602005014135 Country of ref document: DE Date of ref document: 20090604 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOHEST AG |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2325790 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090822 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090822 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20100125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090722 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091130 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E007798 Country of ref document: HU |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091121 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090723 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH) |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20181113 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20181123 Year of fee payment: 9 Ref country code: DK Payment date: 20181109 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SI Payment date: 20181023 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20191014 Year of fee payment: 15 Ref country code: DE Payment date: 20191105 Year of fee payment: 15 Ref country code: HU Payment date: 20191010 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20191108 Year of fee payment: 15 Ref country code: ES Payment date: 20191202 Year of fee payment: 15 Ref country code: FR Payment date: 20191014 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20191116 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20191122 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: MAE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20191130 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191121 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191121 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 429219 Country of ref document: AT Kind code of ref document: T Effective date: 20191121 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20191130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191122 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191122 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20200722 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191121 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191130 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602005014135 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20201201 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20201121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201201 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201130 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201122 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201130 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210601 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201121 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20220202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201122 |